| Literature DB >> 25421512 |
Karl Mann1, Sabine Vollstädt-Klein, Iris Reinhard, Tagrid Leménager, Mira Fauth-Bühler, Derik Hermann, Sabine Hoffmann, Ulrich S Zimmermann, Falk Kiefer, Andreas Heinz, Michael N Smolka.
Abstract
BACKGROUND: Effect sizes of pharmacotherapy in alcoholism are modest. They might improve if subjects could be divided into more homogeneous subgroups and would then be treated targeted to their neurobiological profile. In such an effort, we tested neural cue reactivity as a potential predictor of treatment response to naltrexone. Alcohol-associated cues cause brain activations in mesocorticolimbic networks due to the positive reinforcing properties of alcohol. These activations were reported to be associated with relapse behavior. Naltrexone, an antagonist at the mu-opioid receptor, improves drinking behavior in some but not all patients probably by blocking the positive reinforcement of alcohol. Conversely, acamprosate is proposed to modulate negative reinforcement (withdrawal and cue-induced withdrawal). Identifying subjects with elevated cue reactivity and testing their response to medical treatment could thus improve our understanding of some of the mechanisms underlying pharmacotherapy response.Entities:
Keywords: Acamprosate; Alcohol; Cue Reactivity; Naltrexone; Personalized Medicine; Relapse; fMRI
Mesh:
Substances:
Year: 2014 PMID: 25421512 DOI: 10.1111/acer.12546
Source DB: PubMed Journal: Alcohol Clin Exp Res ISSN: 0145-6008 Impact factor: 3.455